Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23464746 | 1.00 | MEN1 (0.46) | MEN1KMT2AFUCA1S1PR1S1PR5 | |
| SCHEMBL2706345 | 1.00 | MEN1 (0.46) | MEN1KMT2AFUCA1S1PR1S1PR5 | |
| SCHEMBL15148260 | 0.86 | F2 (0.48) | MEN1KMT2AALDH1A1BCHEMCHR1 | |
| SCHEMBL8563102 | 0.86 | F2 (0.48) | MEN1KMT2AALDH1A1BCHEMCHR1 | |
| SCHEMBL17166392 | 0.85 | KMT2A (0.42) | KMT2AFUCA1S1PR1S1PR5ALDH1A1 | |
| SCHEMBL17166396 | 0.84 | S1PR5 (0.53) | FUCA1S1PR1S1PR5ALDH1A1TDP1 | |
| SCHEMBL23415558 | 0.84 | S1PR5 (0.53) | FUCA1S1PR1S1PR5ALDH1A1TDP1 | |
| SCHEMBL22530421 | 0.81 | FUCA1 (0.47) | MEN1KMT2AFUCA1S1PR1S1PR5 | |
| SCHEMBL26428019 | 0.81 | FUCA1 (0.47) | MEN1KMT2AFUCA1S1PR1S1PR5 | |
| SCHEMBL26428016 | 0.81 | FUCA1 (0.47) | MEN1KMT2AFUCA1S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114980976-A | Covalent RAS inhibitors and uses thereof | 锐新医药公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-106588890-B | Antiviral compounds | 吉利德制药有限责任公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-109020961-A | Antiviral compound | 吉利德制药有限责任公司 | 2018-12-18 | — | — | CN | disclosed |
| CN-104230900-B | Antiviral compound | 吉利德制药有限责任公司 | 2018-10-19 | — | — | CN | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| CN-106588890-A | Antiviral compounds | 吉利德制药有限责任公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-104211713-B | Antiviral compounds | 吉利德制药有限责任公司 | 2017-04-12 | — | — | CN | disclosed |
| US-8575118-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8273341-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| CN-102596936-A | Antiviral compounds | GILEAD SCIENCES INC | 2012-07-18 | — | — | CN | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2430014-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MEN1 4292/4885KMT2A 3803/4885FUCA1 2977/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MEN1 4292/4885KMT2A 3803/4885FUCA1 2977/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MEN1 4292/4885KMT2A 3803/4885FUCA1 2977/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MEN1 4292/4885KMT2A 3803/4885FUCA1 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.